Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$273.88 USD
-2.45 (-0.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $274.09 +0.21 (0.08%) 4:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALNY 273.88 -2.45(-0.89%)
Will ALNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
ALNY Down Despite Positive Data From Heart Disease Drug Study
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Other News for ALNY
American Century Focused Dynamic Growth Fund Q2 2024 Commentary
Alnylam Pharma (ALNY) Receives a Buy from Bank of America Securities
TD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Fidelity Select Health Care Portfolio Q2 2024 Review